{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:15:10Z","timestamp":1788243310872,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune effector cell-associated hematotoxicity (ICAHT) is a common and clinically important toxicity after chimeric antigen receptor (CAR) T-cell therapy. The CAR-HEMATOTOX score, also reported as CAR-HT, is a baseline risk score proposed to identify patients at higher risk of hematotoxicity and related adverse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, the Web of Science, and the Cochrane Library on June 19, 2026. Included studies compared high- and low-risk groups defined by the CAR-HEMATOTOX score after CAR T-cell therapy for hematologic malignancies and reported extractable data on hematologic toxicity, infection, survival, or other predefined clinical outcomes. Random-effects inverse-variance meta-analysis was performed only when at least three independent, clinically compatible estimates were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three publications were included in the evidence inventory. For ICAHT, high risk was associated with higher odds (pooled OR 5.58, 95% CI 1.98 to 15.73; I\u00b2=60.8%). For overall survival (OS), high risk was associated with worse OS (pooled HR 3.36, 95% CI 2.20 to 5.11; I\u00b2=0.0%). For progression-free survival (PFS), high risk was associated with worse PFS (pooled HR 2.74, 95% CI 1.81 to 4.15; I\u00b2=32.3%). For severe infection, high-risk status was associated with higher odds (pooled OR 5.18, 95% CI 2.78 to 9.67; I\u00b2=37.8%). Exploratory analyses suggested higher early red blood cell and platelet transfusion requirements in high-risk patients, whereas severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were not significantly associated with high-risk status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A high CAR-HEMATOTOX score was associated with greater risk of ICAHT, higher odds of severe infection, and worse survival outcomes after CAR T-cell therapy for hematologic malignancies. These findings suggest that the CAR-HEMATOTOX score may be a clinically relevant risk-stratification marker, but the evidence remains observational and exploratory; standardized outcome definitions, prospective validation, and clearer handling of overlapping cohorts are needed before the score can be used as a stand-alone decision tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/view\/CRD420261435303<\/jats:ext-link>\n                      , identifier 420261435303.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1928438","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:40Z","timestamp":1788240940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-HEMATOTOX score as a predictor of hematotoxicity, infection, and survival after CAR T-cell therapy in hematologic malignancies: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Juncheng","family":"Wei","sequence":"first","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Jiang","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103267","article-title":"Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis","volume":"84","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016689","article-title":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL","volume":"9","author":"de Boer","year":"2025","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-026-01455-5","article-title":"Management of hematological toxicities after BCMA-directed CAR-T cell therapy","volume":"16","author":"Cook","year":"2026","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell-associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017526","article-title":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia","volume":"10","author":"Valtis","year":"2026","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.888","article-title":"Prospective validation of CAR-HEMATOTOX and a simplified version predict survival in patients with large B-cell lymphoma treated with anti-CD19 CAR T-cells: Data from CART-SIE study","volume":"31","author":"Stella","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.06.021","article-title":"Prolonged cytopenia after idecabtagene vicleucel for multiple myeloma is associated with poor overall survival","author":"Kaur","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.07.003","article-title":"Prognostic implications of splenomegaly in BCMA-directed CAR T-cell therapy for relapsed myeloma","volume":"31","author":"Wiemers","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2025.05.04","article-title":"Can one scoring system fit all? Comparative validation of CAR-HEMATOTOX, ALL-HEMATOTOX, and eIPM for predicting immune effector cell-associated hematotoxicity following CAR-T therapy in hematologic Malignancies","volume":"37","author":"Zhang","year":"2025","journal-title":"Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70229","article-title":"Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma","volume":"9","author":"Airosa Pardal","year":"2025","journal-title":"HemaSphere"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2620889","article-title":"CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse events","volume":"22","author":"Sr\u0161en","year":"2026","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012436","article-title":"Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL","volume":"13","author":"Culbert","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","article-title":"Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma","volume":"15","author":"Winkelmann","year":"2025","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.048","article-title":"Systemic inflammation and CAR-T specific toxicities as major drivers of nonrelapse mortality: Analysis from the Italian prospective observational CART-SIE study","volume":"32","author":"Barone","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.073","article-title":"Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-Score, a novel prediction model","volume":"30","author":"Nakamura","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"HemaSphere"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2026.1729151","article-title":"Construction and validation of a nutritional status (CONUT)-based nomogram for predicting prolonged hematological toxicity in relapsed\/refractory multiple myeloma after CAR-T cell therapy","volume":"13","author":"Xu","year":"2026","journal-title":"Front Nutr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100020","article-title":"Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort","volume":"1","author":"Reynolds","year":"2025","journal-title":"Blood Immunol Cell Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:41Z","timestamp":1788240941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1928438"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1928438","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1928438"}}